Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 10/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | FPR3 | P25089 | 4/20 | 0.34 |
| ▸ | FPR2 | P25090 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17040901 | 0.83 | BACE1 (0.43) | BACE1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL4837190 | 0.83 | GHSR (0.43) | BACE1NPC1RAB9AGHSR | |
| SCHEMBL306307 | 0.83 | GHSR (0.43) | BACE1NPC1RAB9AGHSR | |
| SCHEMBL18614341 | 0.83 | GHSR (0.43) | BACE1NPC1RAB9AGHSR | |
| SCHEMBL4835508 | 0.81 | DPP8 (0.39) | BACE1GHSR | |
| SCHEMBL4835493 | 0.81 | DPP8 (0.39) | BACE1GHSR | |
| SCHEMBL17605455 | 0.79 | KDM4E (0.35) | BACE1RECQL | |
| SCHEMBL24781183 | 0.77 | NPC1 (0.32) | BACE1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL30062444 | 0.77 | NPC1 (0.32) | BACE1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL24781343 | 0.77 | NPC1 (0.32) | BACE1NPC1RECQLRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353817-A1 | INTERLUKIN-17A INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353817-A1 | INTERLUKIN-17A INHIBITORS AND USES THEREOF | IL17A, IL15, IL23R | BACE1 751/4885NPC1 2168/4885RECQL 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.